Complete peripheral blood cell analysis (red blood cells, platelets, white blood cells):
– Overall health assessment.
– Early diagnosis of blood diseases (anemia, leukemia, thrombocytopenia…) and infectious diseases.

AFP liver tumor marker test:
– The AFP (Alpha-fetoprotein) test is a simple test, often used to screen and monitor the progress of cancer treatment, especially liver cancer. However, the AFP test is not a definitive diagnosis and needs to be combined with other tests to draw an accurate conclusion.
– Normal AFP levels do not rule out cancer.

CEA colorectal tumor marker test:
– CEA is a protein produced by some cancer cells. The CEA test is often used to screen for and monitor the progress of cancer treatment, especially colorectal cancer.
– Normal CEA levels do not rule out cancer.

Pancreatic tumor marker test CA 19-9:
– CA 19-9 is a glycoprotein produced by some cancer cells, especially pancreatic cancer. The CA 19-9 test is often used to screen, monitor, and assess the prognosis of certain types of cancer.
– Normal CA 19-9 levels do not rule out cancer.

Prostate-specific antigen (PSA) test:
– PSA is a protein produced by the prostate gland. Increased PSA levels not only indicate the possibility of prostate cancer, but can also help detect other diseases such as prostatitis, benign prostatic hyperplasia,…
– Normal PSA levels do not rule out cancer.

Cyfra 21-1 lung tumor marker test:
– Cyfra 21-1 has certain significance in screening lung cancer patients, especially in distinguishing lung cancer from other benign lung diseases.
– Normal Cyfra 21-1 levels do not rule out cancer.

CA 72-4 gastric tumor marker test:
– CA 72-4 is a tumor cell antigen, commonly used to detect and monitor the growth of tumors in the body, especially stomach cancer.
– Normal CA 72-4 levels do not rule out cancer.